Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|April 8, 2020
Quiz: What RA drugs are under study as possible COVID-19 treatments?
Author(s)Ingrid Torjesen
The American College of Rheumatology has issued a series of COVID-19 guiding principles for healthcare professionals who treat patients with rheumatic disease. In this quiz, we highlight a few of the key points the organization, and other healthcare experts, have made in recent weeks.
Advertisement
The American College of Rheumatology has issued a series of COVID-19 guiding principles for healthcare professionals who treat patients with rheumatic disease. In this quiz, we highlight a few of the key points the organization, and other healthcare experts, have made in recent weeks.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement